Veracyte, Inc. - Common Stock (NQ:VCYT)

45.81 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Veracyte Announces Release of Inaugural ESG Report

May 03, 2023

From Veracyte, Inc.

Via Business Wire

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

May 02, 2023

From Veracyte, Inc.

Via Business Wire

Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

May 01, 2023

From Veracyte, Inc.

Via Business Wire

A Preview Of Veracyte's Earnings ↗

February 21, 2023

Via Benzinga

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

April 29, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

April 27, 2023

From Veracyte, Inc.

Via Business Wire

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

April 17, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023

April 13, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

April 12, 2023

From Veracyte, Inc.

Via Business Wire

Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗

April 01, 2023

Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...

Via Talk Markets

Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners

March 15, 2023

From Veracyte, Inc.

Via Business Wire

7 Biotech Stocks That Could Be the Next Big Thing ↗

March 15, 2023

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

Via InvestorPlace

Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

March 11, 2023

From Veracyte, Inc.

Via Business Wire

Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? ↗

March 10, 2023

This diagnostics test maker has held up well over the last year.

Via The Motley Fool

Veracyte to Participate in Upcoming Investor Conferences

February 27, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

February 22, 2023

From Veracyte, Inc.

Via Business Wire

SMID Cap Life Science Update: Are You An Investor Or Trader? ↗

February 20, 2023

Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.

Via Talk Markets

Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

February 15, 2023

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For February 22, 2023 ↗

February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Via Benzinga

New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

February 13, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

February 06, 2023

From Veracyte, Inc.

Via Business Wire

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

February 01, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

February 01, 2023

From Veracyte, Inc.

Via Business Wire

Better Long-Term Buy in 2023: Exact Sciences or Veracyte? ↗

January 24, 2023

As cancer screenings are becoming covered more often, both companies stand to gain.

Via The Motley Fool

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

January 23, 2023

From Exagen Inc.

Via GlobeNewswire

Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock ↗

January 18, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗

January 18, 2023

Via Benzinga

This Small-Cap Stock Is a No-Brainer Buy ↗

January 18, 2023

This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.